Кардиоренальный анемический синдром: возможности коррекции с помощью железа сахарата


В.В. Фомин, Л.В. Козловская, Ю.С. Милованов, Л.Ю. Милованова

ГОУ ВПО “Первый МГМУ им. И.М. Сеченов” Минздравсоцразвития России, Москва
Обсуждается кардиоренальный анемический синдром; особое внимание уделено роли железа сахарата в его коррекции.

Литература


1. Ruggenenti P., Schieppatti A., Remuzzi G. Progression, regression, remission of renal diseases. Lancet 2001; 357: 1601–1608.
2. Baigent C., Burbury K., Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet 2000; 356: 147–152.
3. Ratcliffe P.J. Molecular biology of erythropoietin. Kidney Int. 1993; 44: 887–904.
4. Тареев Е.М. Анемия брайтиков. М., 1929, Издательство факультетской клиники 1-го МГУ.
5. Silverberg D.S., Wexler D., Iaina A. The importance of anemia and its correction in the management of severe congestive heart failure Eur. J. Heart Fail. 2002; 4: 681–686.
6. Ronco C., McCullough P., Anker S.D. et al.; Acute Dialysis Quality Initiative (ADQI) consensus group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J. 2010; 31(6): 703 –711.
7. von Haehling S., Anker S.D. Cardio-renal anemia syndrome. Contrib. Nephrol. 2011; 171: 266–273.
8. Silverberg D.S., Wexler D., Blum M., Iania A. The cardio-renal syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin. Nephrol. 2003; 60: S93–S102.
9. Levin A., Thompson C.R., Ethier J. et al. Left ventricular mass index increase in early renal disease: impact of decline of hemoglobin. Am. J. Kidney Dis. 1999; 34: 768–776.
10. Kazmi W., Kausz A., Khan S. et al. Anemia: an early complication of chronic renal insufficiency. Am. J. Kidney Dis. 2001; 38: 803–812.
11. Ezekowitz J.A., McAlister F.A., Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes insights from a cohort of 12 065 patients with new-onset heart failure. Circulation. 2003;107: 223–225.
12. Vaziri N.D. Erytropoetin and transferrin metabolism in nephrotic syndrome. Am. J. Kidney Dis. 2001; 38: 1–8.
13. Eschbach J.W. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int. 1989; 35: 134–148.
14. Foley R.N., Parfrey P.S., Harnett J.D. et al. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am. J. Kidney Dis. 1996; 28: 53–61.
15. van der Meer P., van Gilst W.H., van Veldhuisen D.J. Anemia and congestive heart failure. Circulation 2003; 108: E41–E42.
16. Cohen N., Gorelik O., Almoznino-Sarafian D. et al. Renal dysfunction in congestive heart failure, pathophysiological and prognostic significance. Clin. Nephrol. 2004; 61: 177–184.
17. Torre-Amione G., Bozkurt B., Deswal A. et al. An overview of tumor necrosis factor alfa and the failinig human heart. Curr. Opin. Cardiol. 1999; 14: 206–210.
18. Macdougall I.C. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol. Dial. Transplant. 1999; 14: 1836–1841.
19. Anand I.S., Chandrashekhar Y., Ferrari R. et al. Pathogenesis of edema in chronic anemia: studies of body water and sodium, renal function, haemodynamics and plasma hormones. Br. Heart J. 1993; 70: 357–362.
20. Weiskopf R.B., Viele M.K., Feiner J. et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. J.A.M.A. 1998; 279: 217–221.
21. London G.M, Fabiani F., Marchais S.J. et al. Uremic cardiomyopathy: an inadequate left ventricular hypertrophy. Kidney Int. 1987; 31: 973–980.
22. Greaves S.C., Gamble G.D., Collins J.F. et al. Determinants of left ventricular hypertrophy and systolic dysfunction in chronic renal failure. Am. J. Kidney Dis. 1994; 24: 768–776.
23. Madore F., Lowrie E.G., Brugnara C. et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J. Am. Soc. Nephrol. 1997; 8: 1921–1929.


24. Козловская Л.В., Милованов Ю.С., Фомин В.В. et al. Анемическая кардиомиопатия. Анемия. 2004; 1: 29–35.
25. McClellan W., Flanders W.D., Langston R.D. et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J. Am. Soc. Nephrol. 2002; 13: 1928–1936.
26. Horwich T.B., Fonarow G.C., Hamilton M.A. et al. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 2002; 39: 1780–1786.
27. AlAhmad A., Rand W.M., Manjunath G. et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J. Am. Coll. Cardiol. 2003; 38: 955–962.
28. Anker S.D., Sharma R., The syndrome of cardiac cahexia. Int. J. Cardiol. 2002; 85: 51–66.
29. Anand I., McMurray J.J.V., Whitmore J. et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 2004; 110: 149–154.
30. Deicher R., Horl W.H. Anaemia as a risk for the progression of chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 2003; 12: 139–143.
31. Mohanram A., Zhang Z., Shahinfar S. et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004; 66:1131–1138.
32. Neff M.S., Kwan E.K., Persoff M. et al. Hemodynamics of uremic anemia. Circulation 1971; 43: 876–883.
33. Jungers P., Massy Z.A., Nguyen Khoa T. et al. Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol. Dial. Transplant. 1997; 12: 2597–2602.
34. Mac Mahon L.P., Mason K., Skinner S.L. et al. Effects of hemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol. Dial. Transplant. 2000; 15: 1425–1430.
35. Macdougall I.C., Chandler G., Elston O., Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit. Am. J. Kidney Dis. 1999; 34 (Suppl. 2): S40–S46.
36. Van Vyck D.B. Management of early renal anaemia: diagnostic work-up, iron therapy, epoetin therapy. Nephrol. Dial. Transplant. 2000; 15 (Suppl. 3): 36–39.
37. Sander-Plassmann G., Horl W. Importance of iron supply for erythropoietin therapy. Nephrol. Dial. Transplant. 1995; 10: 979–987.
38. Сharytan C., Levin N., Al-Saloum M. et al. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American Clinical Trial. Am. J. Kidney Dis. 2001; 37: 300–307.
39. Singh H., Reed J., Noble S., Cangiano J.L., Van Wyck D.B.; United States Iron Sucrose (Venofer) Clinical Trials Group. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin. J. Am. Soc. Nephrol.
2006; 1(3): 475–482.
40. Li H., Wang S.X. Intravenous iron sucrose in peritoneal dialysis patients with renal anemia. Perit. Dial. Int. 2008; 28(2): 149–154.
41. Malovrh M., Hojs N., Premru V. The influence of need-based, continuous, low-dose iron replacement on hemoglobin levels in hemodialysis patients treated with erythropoiesis-stimulating agents. Artif. Organs. 2011; 35(1): 63–68.
42. Solak Y., Atalay H., Guney I. Comparison of adverse-event profiles of intravenous low-molecular-weight iron dextran and iron sucrose in peritoneal dialysis patients. Ren. Fail. 2011; 33(3): 307–311.
43. Pollak V.E., Lorch J.A., Shukla R., Satwah S. The importance of iron in longterm survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data. BMC Nephrol. 2009;10:6.
44. Comín-Colet J., Ruiz S., Cladellas M. et al. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes. J. Card. Fail. 2009; 15(9): 727–735.
45. Rottembourg J., Kadri A., Leonard E., et al. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant. 2011 Feb 25. [Epub ahead of print].


Об авторах / Для корреспонденции


Фомин В.В. – профессор кафедры терапии и профболезней медико-профилактического факультета, декан факультета довузовского образования ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.
E-mail: fomin_vic@mail.ru;
Козловская Л.В. – профессор кафедры терапии и профболезней медико-профилактического факультета ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.
Милованов Ю.С. – ведущий научный сотрудник отдела нефрологии НИИ уронефрологии и репродуктивного здоровья человека ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, д.м.н.
Милованова Л.Ю. – научный сотрудник отдела нефрологии НИИ уронефроло-гии и репродуктивного здоровья человека ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития России, к.м.н.


Похожие статьи


Бионика Медиа